rs267606599
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_001042492.3(NF1):c.3113+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,084 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001042492.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250808Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135668
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461084Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 726834
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:10
This sequence change affects a donor splice site in intron 23 of the NF1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs267606599, gnomAD 0.003%). Disruption of this splice site has been observed in individuals with neurofibromatosis, type 1 (PMID: 16944272, 18484666, 25293717, 26962827, 26969325). ClinVar contains an entry for this variant (Variation ID: 345). Studies have shown that disruption of this splice site results in skipping of exon 23, but is expected to preserve the integrity of the reading-frame (PMID: 7633431). For these reasons, this variant has been classified as Pathogenic. -
- -
- -
This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS3,PS4. -
- -
- -
This variant is reported in the ClinVar database as pathogenic by 13 submitters (Accession ID: VCV000000345.39). This canonical splice-site variant is likely to result in aberrant splicing leading to either formation of a truncated protein product or the transcript to undergo nonsense-mediated mRNA decay. -
- -
PVS1, PS3 -
- -
not provided Pathogenic:2
Canonical splice site variant demonstrated to result in abnormal splicing leading to an in-frame deletion of a critical region (Purandare 1995); A different nucleotide change at this same canonical splice site (c.3113+1G>T) has been reported as pathogenic in ClinVar and at GeneDx (ClinVar SCV# SCV000253824.3; Landrum 2016); Also known as IVS18+1G>A; This variant is associated with the following publications: (PMID: 10712197, 25293717, 7633431, 16944272, 23913538, 26969325, 26962827, 18484666, 31370276, 31776437, 31533797) -
The NF1 c.3113+1G>A variant (rs267606599), also known as IVS18+1G>A in legacy nomenclature, is reported in the literature in several individuals affected with neurofibromatosis type 1 (Griffiths 2007, Kang 2020, Pros 2020). This variant is also reported in ClinVar (Variation ID: 345). This variant is only observed on one allele in the Genome Aggregation Database, indicating it is not a common polymorphism. This variant disrupts the canonical splice donor site of intron 23, and functional analyses of the variant protein show this variant leads to skipping of exon 23 (Upadhyaya 2008, Purandare 1995). Based on available information, this variant is considered to be pathogenic. References: Griffiths S et al. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer. 2007;6(1):21-34. PMID: 16944272. Kang E et al. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. J Hum Genet. 2020 Jan;65(2):79-89. PMID: 31776437. Pros E et al. Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat. 2008 Sep;29(9):E173-93. PMID: 18546366. Purandare SM et al. Characterisation of a novel splice donor mutation affecting position +1 in intron 18 of the NF-1 gene. Hum Mol Genet. 1995 Apr;4(4):767-8. PMID: 7633431. Upadhyaya M et al. Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum Mutat. 2008 Aug;29(8):E103-11. PMID: 18484666. -
Neurofibromatosis, type 1;C4024216:Tibial pseudarthrosis Pathogenic:1
- -
NF1-related disorder Pathogenic:1
The NF1 c.3113+1G>A variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported in multiple unrelated individuals with neurofibromatosis type 1 (see for example - Upadhyaya et al. 2008. PubMed ID: 18484666; Table S1 - Pros et al. 2008. PubMed ID: 18546366). Splicing studies found this variant results in skipping of exon 18 which is predicted to result in an inframe deletion (Table S1 - Pros et al. 2008. PubMed ID: 18546366). This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD. Variants that disrupt the consensus splice donor site in NF1 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
The c.3113+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 23 of the NF1 gene. This mutation has been detected in multiple individuals who fulfilled diagnostic criteria for neurofibromatosis type 1 (Upadhyaya M et al. Hum. Mutat., 2008 Aug;29:E103-11; Thomas L et al. Eur. J. Hum. Genet., 2012 Apr;20:411-9; Emmerich D et al. Eur. J. Hum. Genet., 2015 Jun;23:870-3; Hutter S et al. Hum. Genet., 2016 May;135:469-75). In addition to the clinical data presented in the literature, RNA studies have demonstrated that the alteration results in skipping of exon 23, leading to an in-frame deletion in a region critical to protein function (Purandare SM et al. Hum. Mol. Genet., 1995 Apr;4:767-8; Ars E et al. J. Med. Genet., 2003 Jun;40:e82; Pros E et al. Hum. Mutat., 2008 Sep;29:E173-93; Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Hereditary cancer-predisposing syndrome Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at